Default: Neurodegenerative disease management

ISSN: 1758-2024

Journal Home

Journal Guideline

Neurodegenerative disease management Q2 Unclaimed

Taylor and Francis Ltd. United Kingdom
Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

Neurodegenerative disease management is a journal indexed in SJR in Neurology (clinical) with an H index of 32. It has an SJR impact factor of 0,618 and it has a best quartile of Q2. It has an SJR impact factor of 0,618.

Type: Journal

Type of Copyright:

Languages:

Open Access Policy:

Type of publications:

Publication frecuency: -

WOS
Categories: Medicine (miscellaneous) (Q2) Neurology (clinical) (Q3)
Price

- €

Inmediate OA

NPD

Embargoed OA

- €

Non OA

Metrics

Neurodegenerative disease management

0,618

SJR Impact factor

32

H Index

30

Total Docs (Last Year)

105

Total Docs (3 years)

1223

Total Refs

257

Total Cites (3 years)

100

Citable Docs (3 years)

2.59

Cites/Doc (2 years)

40.77

Ref/Doc

Comments

No comments ... Be the first to comment!



Best articles by citations

Alexithymia in Parkinson's disease: a point of view on current evidence

View more

Mild cognitive impairment definitions: more evolution than revolution

View more

Journal Watch

View more

Introducing Volume 9 ofNeurodegenerative Disease Management

View more

Nutritional management of individuals with Huntington's disease: nutritional guidelines

View more

Care considerations for dementia in people with Down's syndrome: a management perspective

View more

Journal Watch: Our panel of experts highlight the most important research articles across the spectrum of topics relevant to the field of neurodegenerative disease management

View more

Journal Watch: Our panel of experts highlight the most important research articles across the spectrum of topics relevant to the field of neurodegenerative disease management.

View more

Deep brain stimulation for Parkinson's disease: current status and future outlook

View more

Depression in the early stages of Huntington disease

View more

Could miRNA expression changes be a reliable clinical biomarker for Parkinson's disease?

View more

New tools for the evaluation of patients with neurodegenerative diseases

View more
SHOW MORE ARTICLES

Cognitive remediation to enhance mobility in older adults: the CREM study

View more

IPX066: a new intermediate- and extended-release carbidopa-levodopa formulation

View more

Diagnostic evaluation and monitoring of patients with posterior cortical atrophy

View more

Current and future potential of retinal optical coherence tomography in multiple sclerosis with and without optic neuritis

View more

Outcome measurement in neurodegenerative disease: attributes, applications & interpretation

View more

The role of oligodendroglial dysfunction in amyotrophic lateral sclerosis

View more

Alzheimer's disease and vascular dementia: one potentially preventable and modifiable disease. Part I: Pathology, diagnosis and screening

View more

Clinical insights into use of apomorphine in Parkinson's disease: tools for clinicians

View more

Defining premotor Parkinson's disease: a window of opportunity for neuroprotection?

View more

Unpredictable sensations: can stochastic resonance help in Parkinson's disease?

View more

Depression versus dementia: is this construct still relevant?

View more

Neurophysiology in Huntington's disease: an update

View more

FAQS